# A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

> **NCT04486781** · PHASE2 · UNKNOWN · sponsor: **Vasgene Therapeutics, Inc** · enrollment: 38 (estimated)

## Conditions studied

- Metastatic Urothelial Carcinoma

## Interventions

- **DRUG:** Pembrolizumab + sEphB4-HSA

## Key facts

- **NCT ID:** NCT04486781
- **Lead sponsor:** Vasgene Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-14
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486781, "A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04486781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*